NAPRT

Nicotinate phosphoribosyltransferase · Q6XQN6 · NAPRT on Sugi Atlas →

67,939 patent compounds predicted against NAPRT, 50,573 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL107538	0.67	3/20
SCHEMBL40612	0.54	3/20
Pyridine (SCHEMBL30127)	0.47	3/20
SCHEMBL69939	0.46	3/20
SCHEMBL78249	0.45	3/20
SCHEMBL87737	0.43	3/20
Phthalic Acid (SCHEMBL107074)	0.38	3/20
Antipyrine (SCHEMBL20452)	1.00	2/20
Isonicotinic Acid (SCHEMBL2197)	0.94	2/20
Terephthalic Acid (SCHEMBL1655)	0.73	2/20
Antipyrine (SCHEMBL24801)	0.69	2/20
Pyridine (SCHEMBL1536)	0.69	2/20
Pyridine (SCHEMBL39580)	0.69	2/20
Terephthalic Acid (SCHEMBL104074)	0.69	2/20
Phthalic Acid (SCHEMBL1808)	0.68	2/20
Phthalic Acid (SCHEMBL22453)	0.65	2/20
Phthalic Acid (SCHEMBL45285)	0.65	2/20
Phthalic Acid (SCHEMBL105219)	0.65	2/20
Phthalic Acid (SCHEMBL106333)	0.65	2/20
Terephthalic Acid (SCHEMBL22420)	0.65	2/20

Clinical trials — most relevant to NAPRT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis	PHASE4	NOT_YET_RECRUITING
cindilizumab + Bevacizumab + Coenzyme I for Injection in Unresectable Hepatocellular Carcinoma	PHASE4	UNKNOWN
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS	PHASE3	COMPLETED
A Study to Assess APO866 for the Treatment of Advanced Melanoma	PHASE2	COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Nicotinamide Riboside in Systolic Heart Failure	PHASE1/PHASE2	COMPLETED
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome	PHASE1/PHASE2	COMPLETED
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma	PHASE2	COMPLETED
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration	PHASE2	COMPLETED
The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging	PHASE2	RECRUITING
The Safety and Efficacy of an NAD+ Boosting Product Together With a Low Carbohydrate Diet in Adults With Mild Hypertension and Eligible for Normal-standard-of-care	PHASE2	COMPLETED
Effect of Nicotinamide in Friedreich's Ataxia	PHASE2	UNKNOWN
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy	PHASE1	COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease	PHASE1	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery	nan	NOT_YET_RECRUITING
Sirtuin1 in COVID19 Patients	nan	UNKNOWN
Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension	nan	RECRUITING
IV Administration of ChromaDex's Niagen® as Compared to NAD+	nan	UNKNOWN
Inflammation in COPD and the Effect of Nicotinamide Riboside	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations	nan	UNKNOWN
Nicotinamide Riboside Clinical Trial for GWI	nan	RECRUITING
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NAPRT binder may also engage these)

Protein	Name	Similarity
A5PK51	—	1.000	A5PK51 →
Q8CC86	—	0.985	Q8CC86 →
Q6XQN1	—	0.982	Q6XQN1 →
Q96FB5	—	0.953	Q96FB5 →
Q9BQD7	—	0.953	Q9BQD7 →
Q5E9V4	—	0.949	Q5E9V4 →
HDAC10	Polyamine deacetylase HDAC10	0.947	landscape →
POLM	DNA-directed DNA/RNA polymerase mu	0.945	landscape →
Q8VCA8	—	0.944	Q8VCA8 →
Q96FV2	—	0.944	Q96FV2 →
Q2TBI8	—	0.943	Q2TBI8 →
Q6AYG0	—	0.942	Q6AYG0 →
Q8BZG5	—	0.942	Q8BZG5 →
P60487	—	0.941	P60487 →
Q9BRQ3	—	0.941	Q9BRQ3 →
Q501J2	—	0.940	Q501J2 →
Q5T9C9	—	0.939	Q5T9C9 →
Q8IZ69	—	0.939	Q8IZ69 →
Q8N9H8	—	0.939	Q8N9H8 →
Q0V8F1	—	0.939	Q0V8F1 →
Q53HV7	—	0.938	Q53HV7 →
Q5IS64	—	0.938	Q5IS64 →
Q17QS4	—	0.938	Q17QS4 →
Q5F4B1	—	0.938	Q5F4B1 →
Q3ZBF9	—	0.937	Q3ZBF9 →
E1BE10	—	0.937	E1BE10 →
O00587	—	0.937	O00587 →
Q8NE01	—	0.937	Q8NE01 →
Q5SWZ9	—	0.936	Q5SWZ9 →
Q9DD16	—	0.936	Q9DD16 →